The transcription factors Oct4 and Sox2 are highly expressed in embryonic stem (ES) cells. In conjunction with Klf4 and c-Myc, their over-expression can induce pluripotency in both mouse and human somatic cells, indicating that these factors are key regulators of the signaling network necessary for ES cell pluripotency. Self-renewal is a hallmark of stem cells and cancer and stemness program could play an important role in cancer. Therefore we compared the expression of Oct4, Sox2, Klf4 and c-Myc in 40
Introduction
Oct3/4, Sox2, Klf4, c-Myc are expressed in embryonic stem (ES) cells, and their over-expression can induce pluripotency in both mouse and human somatic cells, indicating that these factors regulate the developmental signaling network necessary for ES cell pluripotency [1; 2] .
Cancer stem cells refer to a subset of tumor cells that has the ability to self-renew and generate tumor heterogeneity [3; 4; 5] .
Oct4 is a major transcription factor that is mandatory for the self-renewal and pluripotency characteristics of ES cells and germ cells. Rare cells that express Oct4 were identified in several somatic cancers [6] . Oct4A expressing cells are present in human benign and malignant prostate glands and the frequency of Oct4A expressing cells increases in prostate cancers [6] . A subpopulation of the Oct4A expressing cells coexpressed Sox2, an ES cell marker [6] . In the intestine, Oct4 expression causes dysplasia by inhibiting cellular differentiation in a manner similar to that in the ES cells [7] .
In the mouse nervous system, Sox2 is expressed in neural stem cells, in early precursors and in few mature neurons, and is essential to maintain the cell proliferative potential [8; 9] . Sox2 is also expressed in several malignant tissues [10; 11; 12; 13] .
These data and the known role of Sox2 in development and cell differentiation suggest that this transcription factor may be relevant to the aberrant growth of tumor cells.
Myc has a gene activation function, a finding consistent with Myc ability to recruit multiple coactivator complexes [14; 15] . The ability of Myc to bind to a staggeringly large number of genomic loci has also been demonstrated in ES cells [16] and is likely to underlie its activity as part of the "magic quartet" of transcription factors that can reprogram somatic cells to pluripotency [1; 17; 18; 19] . High levels of Myc may block cell differentiation and enhance self-renewal of committed and differentiated cells [20] . During tumor progression, Myc would promote the formation of cancer-initiating cells that retain developmental plasticity. Expression of Myc in hematopoietic stem cells leads to the rapid formation of pre B-cell lymphomas if apoptosis is blocked by coexpression of Bcl-2.
Cells derived from these lymphomas can be differentiated into either B-lymphocytes or macrophages in vitro [21] . Similarly, cells derived from liver tumors generated using an inducible Myc transgene differentiate into hepatocytes and biliary cells that go on to form bile ducts when the transgene is turned off [22] . A key function of Myc during normal development is to drive expansion of transit amplifying cells. Due to this unique combination of properties, oncogenic deregulation of Myc expression generates cells possessing a tumor phenotype that has no counterpart during normal development [20] .
Kruppel-like factor 4 (Klf4) is a transcription factor expressed in a wide variety of tissues in humans and is important for many different physiological processes, including development, differentiation, and maintenance of normal tissue homeostasis [23] . Klf4 is a transcription factor that can either activate or repress transcription, depending on the target gene. Klf4 can function as an oncogene or a tumor suppressor depending on the type of cancer involved [23] . Klf4 is an anti-proliferative factor in differentiated epithelia, and acts as a tumor suppressor in gastrointestinal cancers [24; 25] . However, Klf4 might also act as an oncogene [26] . It is overexpressed in laryngeal squamous cell carcinoma as an early event in its progression [27] . Klf4 expression is increased in ductal carcinoma of the breast [28] and is associated with an aggressive phenotype and poorer prognosis [29] . In the skin, overexpression of Klf4 results in hyperplasia and dysplasia, eventually leading to squamous cell carcinoma [30; 31] .
Recently, Ben-Porath et al. identified a subset of ES-cell associated transcription regulators that are highly expressed in poorly differentiated tumors revealing a link between genes associated with ES cell identity and the histopatology of tumors [32] .
Cancers arise from a cancer stem cell, able of self-renewal and forming tumor hereterogeneity. The frequency of cancer stem cells is a matter of debate, depending of the technique used to detect it and the cancer type [5; 33] . Given the critical role of 
Methods

Databases
We used Oncomine cancer microarray database (http://www.oncomine.org) [34] , Amazonia database (http://amazonia.montp.inserm.fr/) [35] and RAGE database (http://rage.montp.inserm.fr.gate2.inist.fr) [36] to study gene expression of Oct3/4, Sox2, Klf4 and c-Myc in 40 human tumor types and their normal tissue counterparts as indicated in Table 1 . In order to compare the gene expression in a tumor type to its normal counterpart, gene expression data from a same study, performed with the same methodology, were used. The gene expression data were log transformed, median centered per array, and the standard deviation was normalized to one per array [34] . A gene was considered as overexpressed when its mean value in tumor samples was significantly higher to its mean value in the normal tissue counterpart using a t test (P  .05).
Statistical analysis
Statistical comparisons were done with Mann Whitney or student t-test.
Results and discussion
We investigated the expression of Oct3/4, Sox2, Klf4 and c-Myc in cancer using publicly available gene expression data. The 40 tumor types investigated corresponded to 4 hematological malignancies and 36 solid tumors (Table 1) .
Oct4 is overexpressed in solid and hematological malignancies
We found Oct4 overexpression in 1/4 hematological cancers and 10/36 solid tumors ( Table 1 ). Overexpression of Oct4 was found in in CLL; oligodendroglioma, glioblastoma multiforme and astrocytoma; in bladder carcinoma; in primary colon cancer; in lung adenocarcinoma; in prostate cancer; in testis tumor; in ovarian carcinoma; in pancreatic cancer and in clear cell carcinoma compared to their normal counterpart tissues (Supplementary Figure S1 ).
Sox2 is overexpressed in solid tumors
Sox2 was significantly overexpressed in 7/36 solid tumors ( Table 1 ). Overexpression of Sox2 was found in brain cancers; in hepatocellular carcinoma; in bladder carcinoma; in primary colon cancer; in lung adenocarcinoma; in prostate cancer and in seminoma compared to their normal counterpart tissues (Supplementary Figure S2 ).
KLF4 is overexpressed in all hematological malignancies and in some solid tumors
Klf4 was significantly overexpressed in in 1/4 hematological cancers and 7/36 solid tumors ( Table 1 ): in acute lymphoblastic leukemia; in hairy cell leukemia; in multiple myeloma; in brain tumors; in prostate cancer; in yolk sac tumor compared to their normal counterpart tissues (Supplementary Figure S3 ).
c-Myc is overexpressed in solid and hematological malignancies
We found c-Myc overexpression in all hematological cancers and in 10/36 solid tumors ( Table 1) Figure S4 ).
Correlations between Oct4, Sox2, Klf4 and c-Myc expression in tumor cells
Oct4, Sox2, Klf4 and Myc are all co-overexpressed in 2/40 tumors: i.e. in prostate and brain cancers compared to normal counterparts ( Table 1 ). 3 of these 4 factors were cooverexpressed in leukemia, lung tumors and testis cancer compared to their normal conterparts ( Table 1) 
Link between Oct4, Sox2, Klf4 and c-Myc expression and tumor grade
Thus, we sought to find out whether Oct4, Sox2, Klf4 and Myc expression could be associated with tumor progression and prognosis.
Oct4 was significantly overexpressed in glioma grade IV compared to grade II and III; in poorly differentiated breast carcinoma compared to well differentiated tumors from patients; in head and neck cancers grade IV compared to grade I and in metastatic sarcoma compared to non metatstatic sacrcoma ( Table 2 and Supplementary Figure   S5 ). Table 2 and Supplementary Figure S6 ).
Klf4 is overexpressed in metastatic ovarian carcinoma compared to non metastatic ovarian carcinoma; in prostate carcinoma stage III compared to stage II and in primary melanoma tumors N stage 1 compared to N stage 0 ( Table 2 and Supplementary Figure   S7 ). C-Myc is overexpressed in poorly differentiated lung adenocarcinoma compared to well differentiated lung carcinoma; in ovarian carcinoma grade IV compared to grade I; in poorly differentiated pancreatic ductal adenocarcinoma compared to well differentiated pancreatic ductal adenocarcinoma; in breast carcinoma grade III compared to grade I; in breast ductal carcinoma stage N1 compared to stage N0; in mantle cell lymphoma grade IV compared to grade I; in metatstatic sarcoma compared to primary sarcoma and in melanoma stage N1 compared to stage N0 ( Table 2 and Supplementary Figure S8 ).
Sox2 has been found expressed in a variable percentage of cells in several malignant tissues [10; 11; 12; 13] and is essential to maintain the cell proliferative potential of neural stem cells [8; 9] . Furthermore Sox2 is overexpressed in patients with ovarian carcinoma dead at 5 years compared to patients alive at 5 years (P = .001) [37] and in patients with melanoma metastasis tumor dead at 3 years compared to patients alive at 3 years (P = .007) [38] (Table 3 and Figure 1 ). C-Myc is overexpressed in patients with non-small cell lung cancer dead at 5 years compared to patients alive at 5 years (P = .007) [39] ; in patients with glioma dead at 3 years compared to patients alive at 3 years (P = .008) [40] ; in patients with breast carcinoma dead at 5 years compared to patients alive at 5 years (P = .007) [41] ; in patients with diffuse large B-cell lymphoma dead at 5 years compared to patients alive at 5 years (P = .006 and P = .007) [42; 43] ; in patients with Burkitt's lymphoma dead at 5 years compared to patients alive at 5 years (P = .006) [44] and in 1 year relapsing multiple myeloma patients compared to patients with no relapse at 1 year (P = .001) [45] ( Table 3 and Figure 1 ). Oct4 and Klf4 expressions were not associated with prognostic in the 40 tumor types investigated (Table 3) .
Conclusions:
A key goal in cancer research is to identify the mechanism by which cancer stem cells arise and self-renew. We have shown here that at least one gene coding for 1/4 pluripotency factors -Oct4, Sox2, Klf4, and c-Myc -is overexpressed in 18/40 cancer types investigated. In addition, for a given tumour, the expression of these genes is associated with tumor progression or bad prognosis. The activation of an ES cell-like transcriptional program in differentiated adult cells may induce pathologic self-renewal characteristics of cancer stem cells. In particular, it was recently demonstrated that c-Myc activates an embryonic stem cell like program in epithelial cells leading to epithelial tumor initiating cells [46] . Cancer stem cells are so named because they possess qualities reminiscent of normal tissue stem cells including self-renewal, prolonged survival, and the ability to give rise to cells with more differentiated characteristics. Effort is now focused on identifying cancer stem cells in various malignancies, and defining the cells of origin. This review of publicly available data emphasizes the cancer types associated with Oct3/4, Sox2, Klf4 and/or c-Myc overexpression and may encourage further studies to address the role of these pluripotent transcription factors in these cancers. [45] , in alive patients with and dead patients with breast carcinoma, [41] , in MM patients with no relapse, in MM patients with relapse [45] , in alive and dead patients with diffuse large B cell lymphoma [42; 43] , in alive and dead patients with Burkitt's lymphoma [44] , in alive and dead patients with lung cancer [39] , in alive and dead patients with brain cancer [40] .
Figure legends
B. Sox2 expression in alive and dead patients with ovarian carcinoma [37] and in alive and dead patients with melanoma metastasis tumor [38] . Patients with mutliple myeloma without Sox2 expression (Affymetrix call) have a better event free survival (EFS) and overall survival (OAS) than patients expressing Sox2. Table 1 Ovrer-expression of SOX2, OCT4, KLF4 and c-MYC in human tumor types to that of their normal tissue counterparts using publicly available gene expression data, including the Oncomine Cancer Microarray database. Table 2 Association sox2, oct4, Klf4 and c-Myc with tumor grade Table 3 Association of sox2, Oct4, Klf4 and c-Myc with prognosis in cancer. Table 3 Relapse (26) NoRelapse (11) Carrascoetal.CancerCell2006
